Source: ERS Live 2008
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Cazzola (Naples, Italy). Outcomes for COPD pharmacological trials: from lung function to Biomarkers. ERS Live 2008

Member's Comments

No comment yet.

Related content which might interest you: Outcomes for COPD pharmacological trials: from lung function to biomarkers Source: Eur Respir J 2008; 31: 416-469 Year: 2008 Individual dynamic of inflammatory markers as indicators of COPD treatment effectiveness Source: International Congress 2014 – COPD: points to ponder Year: 2014 LATE-BREAKING ABSTRACT: Biomarkers of ECM turnover and clinical relevant outcomes in COPD: Results of the multicenter PROMISE study Source: International Congress 2015 – Notable abstracts in COPD: variety Year: 2015 Lung function decline in COPD trials Source: Eur Respir J 2009; 33: 708-709 Year: 2009 Pharmacological treatment of COPD in the on-sint cohort Source: International Congress 2014 – COPD exacerbations Year: 2014 Functional Respiratory Imaging as a sensitive biomarker to assess therapeutic interventions in lung diseases Source: International Congress 2015 – Functional and imaging techniques for assessing lung, airway and respiratory muscles Year: 2015 Evaluating cardiac safety of tiotropium in patients with COPD: Combined analysis of Holter-ECG data from four trials Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 Lung function with aclidinium/formoterol fixed-dose combination: Pooled analysis of two phase III studies in COPD Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 Roflumilast for stable COPD: Meta-analysis of randomized controlled trials Source: International Congress 2014 – Clinical presentations Year: 2014 Bronchodilator response of advanced lung function parameters depending on COPD severity Source: International Congress 2016 – Functional assessment of the airways Year: 2016 Laboratory and clinical parameters in predicting risk of future exacerbations in both non-smoking and smoking COPD patients Source: International Congress 2014 – Systemic biomarkers for airway diseases Year: 2014 Endpoints in IPF and lung cancer trials: controversies and perspectives Source: Research Seminar 2015 Year: 2015 Lung cancer screening in COPD patients: NLST criteria vs a COPD screening score Source: International Congress 2014 – The assessment of comorbidities Year: 2014 Biomarkers in COPD exacerbation, the role of adiponectin Source: International Congress 2014 – Predictors Year: 2014 Body-plethysmographic measurements of bronchodilator response in stable COPD Source: International Congress 2014 – Airways: reversibility and responsiveness Year: 2014 Assessment of lung function in patients with COPD using the Inspired Sinewave Technique Source: International Congress 2017 – Lung function testing in different patient categories Year: 2017 Lung function and treatment patterns of symptomatic patients with moderate COPD in the CRYSTAL study Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016 Pulmonary hypertension and COPD: Clinical assessment and biomarkers Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension II Year: 2013 The effects of bronchodilators on regional lung sound distribution in patients with COPD Source: Annual Congress 2013 –Respiratory and cardiovascular abnormalities in COPD: the role of exercise, nutritional status and inflammation Year: 2013 Relation of plasma osteopontin levels with the clinical course in patients with COPD Source: International Congress 2014 – Systemic and airway biomarkers Year: 2014